Home  >  Products  >  Bexarotene, Free Acid (Targretin, Targretyn, Targrexin, LGD-1069, LG 1069, LG100069, SR-11247)

Bexarotene, Free Acid (Targretin, Targretyn, Targrexin, LGD-1069, LG 1069, LG100069, SR-11247)

Cat no: B1085-32C


Supplier: United States Biological
Star_fadedStar_fadedStar_fadedStar_fadedStar_faded
0 reviews | Write a Review Pencil
Bexarotene (LGD-1069) is a synthetic retinoid analog with specific affinity for the retinoid X receptor and belongs to a group of compounds called rexinoids. It is an oral, noncytotoxic drug that was approved in Europe and in the U.S.A. for the treatment of refractory advanced-stage cutaneous T-cell lymphomas (CTCL). Solubility: Soluble in DMSO at 65mg/ml. Soluble in ethanol at 10mg/ml with warming; very poorly soluble in water. Maximum solubility in plain water is estimated to be about 10-50uM. Storage and Stability: May be stored at RT for short-term only. Long-term storage is recommended at -20 degrees C. Stable for 12 months. For maximum recovery of product, centrifuge the original vial prior to removing the cap.
Catalogue number: B1085-32C
Size: 100mg
Form: Supplied as a white powder.
Purity: ~99%
References: 1. Gniadecki, R., et al. "The optimal use of bexarotene in cutaneous T-cell lymphoma." Br. J. Dermatol. 157:433-440 (2007). 2. Rigas, J.R. and Dragnev, K.H. "Emerging Role of Rexinoids in Non-Small Cell Lung Cancer: Focus on Bexarotene." The Oncologist 10:22-33 (2005). 3. Wu, K., et al. "The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice." Cancer Res. 62:6376-6380 (2002). 3. Ye,n W.C. and Lamph, W.W. "A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer." Prostate 66:305-316 (2006). 4. Yen, W.C. and Lamph, W.W. "The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma." Mol. Cancer Ther. 4:824-834 (2005). 5. Yen, W.C., et al. "A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer." Clin. Cancer Res. 10:8656-8664 (2004).

Get Quote

  • Best Price Guaranteed
  • Quick Response Time
  • Exclusive Promotions
Enquiry_down_arrow
United States Biological
Get a Quote Direct from
United States Biological

By submitting this form you agree to your details being passed to United States Biological for the purpose of generating the best quote*

Button_on Button_off_biosave Button_off_biosave Button_off_biosave Button_off_biosave Button_off_biosave Button_off_biosave